Tenaya Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 /CourierPR/ -- Tenaya Therapeutics, a clinical-stage biotechnology company focusing on developing therapies for heart disease, will participate in two upcoming investor conferences in September 2026. The company’s management will host meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, and at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15.

Tenaya Therapeutics will also make available a fireside chat from the H.C. Wainwright conference, which will be accessible via the company’s website starting Friday, September 11, at 7:00 AM Eastern Time. The chat will remain available for approximately 30 days.

The company’s pipeline includes several clinical-stage candidates. TN-201 is a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401 is a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301 is a highly specific small molecule HDAC6 inhibitor with potential applications in cardiac, metabolic, and muscular conditions, such as heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD).

Tenaya Therapeutics has developed a portfolio of novel medicines based on genetic insights, aiming to address both rare genetic disorders and more common heart conditions. The company’s integrated internal capabilities include modality-agnostic target discovery and validation, which have driven the development of its pipeline.